Rockefeller Capital Management
CYCN icon

Rockefeller Capital Management’s Cyclerion Therapeutics CYCN Stock Holding History

Rockefeller Capital Management’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-13
Closed -$1K – 2587
2020
Q1 		$1K Hold
13
– – ﹤0.01% 2260
2019
Q4 		$1K Hold
13
– – ﹤0.01% 1970
2019
Q3 		$3K Hold
13
– – ﹤0.01% 1718
2019
Q2 		$3K Buy
+13
New +$3.68K ﹤0.01% 1493

Other funds holding CYCN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rockefeller Capital Management's CYCN Position: Q2 2020 in Review

Rockefeller Capital Management sold out of Cyclerion Therapeutics (CYCN) in Q2 2020, closing a stake of 13 shares — an estimated $1K sold.

Rockefeller Capital Management first reported a position in CYCN in Q2 2019 and held it in 4 quarters. The position peaked at $3K in Q3 2019. 74 funds tracked by Wall St. Rank hold CYCN as of Q2 2020.

  • Rockefeller Capital Management reported no remaining Cyclerion Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Rockefeller Capital Management sold 13 Cyclerion Therapeutics shares in Q2 2020, an estimated $1K.
  • Rockefeller Capital Management first reported a position in Cyclerion Therapeutics in Q2 2019 and held it in 4 quarters.
  • Rockefeller Capital Management's Cyclerion Therapeutics position peaked at $3K in Q3 2019.
  • 74 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q2 2020.

Based on Rockefeller Capital Management's 13F filing for Q2 2020, filed 12 Aug 2020.